LOBE:CC - Orphan Drug Development an Exciting Opportunity to Provide Superior Therapeutics Lobe Sciences CEO Says

2023-04-27 16:00:04 ET

Lobe Sciences (CSE:LOBE,OTCQB:LOBEF) has significantly expanded its portfolio following its acquisition of Altemia & Company. The purchase also sets Lobe Sciences up for revenue generation in the short term, helping secure funds for orphan drug research and development, according to Philip Young, chairman and CEO.

The acquisition gives Lobe Sciences access to the intellectual property and commercial inventory for Altemia, a medical food for the management of sickle cell disease.

“Our team, via the medical food, are putting the plans in place right now, and we've identified potential partners for distribution, which is very important in this marketplace,” Young said. “And we've done the initial clinical research demonstrating that it's better at reducing a biomarker of inflammation, which is a core component of sickle cell. So we have the data necessary and the product necessary to begin selling it into the marketplace.”

For further details see: